切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2014, Vol. 02 ›› Issue (03) : 65 -67. doi: 10.3877/cma.j.issn.2095-5782.2014.03.018

所属专题： 经典病例； 经典病例； 文献；

病例报告

个案报道：三维适形消融治疗肝左叶胆管细胞癌1例
扈彩霞1, 郑加生1,†(), 孙斌1   
  1. 1. 100069　首都医科大学附属北京佑安医院介入中心
  • 收稿日期:2013-06-05 出版日期:2014-08-01
  • 通信作者: 扈彩霞, 郑加生

3-Dimension Conformal Technology Guided Radiofrequency Ablation of liver’s left lobe for Intrahepatic Cholangiocarcinoma: A Case Report

Jiasheng Zheng1,†, Caixia Hu1(), Bin Sun1   

  1. 1. Center of Minimally Invasive Intervention, Beijing You-an Hospital, Capital Medical University, Beijing 100069, P.R.China
  • Received:2013-06-05 Published:2014-08-01
  • Corresponding author: Jiasheng Zheng, Caixia Hu
  • About author:
    Correspondence to: Dr Jiasheng Zheng, Center of Minimally Invasive Intervention, Beijing You-an Hospital, Capital Medical University, Beijing 100069, P.R.China;
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

扈彩霞, 郑加生, 孙斌. 个案报道：三维适形消融治疗肝左叶胆管细胞癌1例[J]. 中华介入放射学电子杂志, 2014, 02(03): 65-67.

Jiasheng Zheng, Caixia Hu, Bin Sun. 3-Dimension Conformal Technology Guided Radiofrequency Ablation of liver’s left lobe for Intrahepatic Cholangiocarcinoma: A Case Report[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(03): 65-67.

肝细胞癌和胆管细胞癌是常见的两种肝脏肿瘤。不能切除的未经治疗的胆管细胞癌患者预后差，尤其是发生门静脉受侵的患者。目前胆管细胞癌尚无有效的治疗手段。射频消融（radiofrequency ablation，RFA)在不能进行手术切除的肝恶性肿瘤治疗中发挥重要作用，在此，我们报道成功运用射频消融治疗伴有门静脉癌栓的肝内胆管细胞癌一例，该患者共计存活26个月。

关键词: 肝内胆管细胞癌, 肿瘤栓子, 射频消融

Hepatocellular carcinoma and cholangiocarcinoma are the two most common malignant liver tumors.The prognosis for patients with untreated unresectable cholangiocarcinoma is depressed,especially to the patient with invasion in the portal vein. It has no effective treatment presently. Radiofrequency ablation (RFA) plays an importmant role in the treatment of unresectable liver tumors.It is considered a viable alternative to surgery for inoperable patients. Here,we report the successful use of CT- guided RFA in a patient with intrahepatic Cholangiocarcinoma with invasion in the portal vein.The patient survived for 26 months.

Key words: intrahepatic cholangiocarcinoma, tumor thrombus, radiofrequency ablation
Figure 1. Contrast-enhanced CT images of 56-year-old woman with intrahepatic cholangiocarcinoma. It revealed left lobe of liver’s lesions and left branch of portal vein was invasive.
Figure 2. Original magnifications, ×200 and ×400,A,B. Hematoxylin and eosin staining showed morphologic evaluation of intrahepatic cholangiocarcinoma obtained from the patient.
Figure 3. Immunohistochemistry for Hepatocyte(C) and CK-19 (D)in the patient. Hepatocyte staining showed that cancer cells were generally negative. A diffusely positive staining was observed in the tumoral cells for CK-19.
Figure 4. CT guided percutaneous RFA. RFA of the tumor thrombus in the left portal vein and the whole left lobe of liver.
Figure 5. Follow up contrast-enhanced CT images after 6 months from the last time of RFA.The patient’s left lobe of liver was ablated completely
1
Park J,Kim MH,Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3 :298-305
2
Burger I,Hong K,Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol2005 ;16 :353-361
3
Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353-1357.
4
Taylor-Robinson SD,Toledano MB,Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales, 1968-1998. Gut. 2001;48:816-820.
5
Davila JA,El-Serag HB. Cholangiocarcinoma: the "other " liver cancer on the rise. Am J Gastroenterol. 2002;97:3199-3200.
6
de Groen PC,Gores GJ,LaRusso NF, et al. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378.
7
Park J,Kim MH,Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3 :298-305
8
Burger I,Hong K,Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol2005 ;16 :353-361
9
Nakeeb A,Tran KQ,Black MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002;132 :555-563
10
Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur. J. Gastroenterol. Hepatol.2007, 19, 615–617
11
Blechacz B. R., Gores G. J.Cholangiocarcinoma. Clin. Liver Dis. 2008,12, 131–150,
12
El-Serag H. B., Engels E. A., Landgren O., Chiao E., Henderson L., Amaratunge H. C., Giordano T. P.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology,2009, 49, 116–123
13
Aljiffry M,Walsh MJ,Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009;15 :4240-4262
14
De Baere T,Deschamps F,Briggs P, et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 2008;248 :1056-1066
15
Cho YK,Kim JK,Kim MY,Rhim H,Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49 :453-459
16
Stang A,Fischbach R,Teichmann W,Bokemeyer C,Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45 :1748-1756
17
Meloni MF,Andreano A,Laeseke PF,Livraghi T,Sironi S,Lee FT Jr. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long-term survival rates. Radiology 2009;253 :861-869
18
Fujii T,Takayasu K,Muramatsu Y,Moriyama N,Wakao F,Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993;23:105–9.
[1] 涂鹏, 张晓航, 董虹美, 陈功立, 冉素真. 超声多普勒评估在双胎输血综合征射频消融减胎术后的应用价值[J]. 中华医学超声杂志（电子版）, 2023, 20(05): 492-497.
[2] 王兴, 张峰伟. 腹腔镜肝切除联合断面射频消融治疗伴微血管侵犯肝细胞癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 580-583.
[3] 黄小龙, 林师佈, 韩霖, 陈有科, 杨彦. 不同淋巴结清扫范围的肝内胆管细胞癌根治性切除术的预后研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 401-404.
[4] 宋铭杰, 韩青雷, 李佳隆, 邵英梅. 内镜下晚期肝外胆管恶性肿瘤消融治疗研究现况[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 340-342.
[5] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[6] 张海涛, 贾哲, 马超, 张其坤, 武聚山, 郭庆良, 曾道炳, 栗光明, 王孟龙. 手术切除与射频消融治疗血管周围型单发小肝癌临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 523-527.
[7] 孟泓宇, 卢逸, 曹彦龙, 戴操, 杨佳伟, 林楠, 徐见亮. 基于PSM比较TACE联合射频消融与单纯射频消融治疗小肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 417-421.
[8] 廖承煜, 江斌华, 黄龙, 王丹凤, 田毅峰, 陈实. 腹腔镜下肝左叶肝内胆管细胞癌根治术优化三步法的应用价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 395-400.
[9] 杨发才, 游川, 雷正清, 李伟男, 段安琪, 邱应和, 李敬东, 程张军. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 389-394.
[10] 于雁宾, 党受琴, 庄云龙, 许世友, 孟令展, 俞鹏, 高远, 李虎, 曹李, 朱震宇. 35例肝血管平滑肌脂肪瘤患者诊治及疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 327-330.
[11] 于小鹏, 陈晨, 陈家璐, 童焕军, 邱应和, 吴泓, 宋天强, 何宇, 毛先海, 翟文龙, 程张军, 李敬东, 耿智敏, 汤朝晖. 肝内胆管细胞癌淋巴结清扫患者生存获益的术前临床病理特征[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 278-283.
[12] 吴添庆, 王炯亮, 郑梽楷, 李文轩, 周仲国. 经动脉放疗栓塞术治疗不可切除肝内胆管细胞癌疗效与安全性Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 190-195.
[13] 莫建涛, 杨沛泽, 曹瑞奇, 马清涌, 王铮, 仵正, 周灿灿. 基于生物信息学分析构建肝内胆管细胞癌患者铁死亡相关lncRNA预后模型[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 185-189.
[14] 李卓群, 任冯刚, 王荣峰, 张东, 耿智敏, 吕毅, 仵正. 胆管癌局部治疗技术应用进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 153-156.
[15] 蒋子涵, 于丰源, 张宏达, 丁蕾, 米利杰, 唐闽. 2023年美国心律学年会心律失常领域最新临床研究进展[J]. 中华心脏与心律电子杂志, 2023, 11(02): 125-128.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号